Efficacy results from the EPCORE^TM NHL-1 study¹

The median follow-up time was 15.7 months (range: 0.3-23.5)

^*EPCORE^™ NHL-1 enrolled patients with ECOG status 0-2, de novo DLBCL, DLBCL transformed from indolent lymphoma, CAR-T naïve, prior CAR-T, and primary refractory disease.
^†Patients who had relapsed or were refractory to prior CAR-T cell therapy were eligible if ≥30 days since last CAR-T cell treatment.
^‡ORR was determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC)
^§A patient is considered to be primary refractory if they are refractory to frontline anti-lymphoma therapy.
^||A patient is considered to be refractory if they experience disease progression or stable disease as best response or disease progression within 6 months after therapy completion.
^¶Analysed using the Kaplan-Meier method.
^aViral infection includes COVID-19, cytomegalovirus chorioretinitis, cytomegalovirus colitis, cytomegalovirus infection, cytomegalovirus infection reactivation, gastroenteritis viral, herpes simplex, herpes simplex reactivation, herpes virus infection, herpes zoster, oral herpes, post-acute COVID-19 syndrome, and varicella zoster virus infection.
^bPneumonia includes COVID-19 pneumonia and pneumonia.
^cUpper respiratory tract infection includes laryngitis, pharyngitis, respiratory syncytial virus infection, rhinitis, rhinovirus infection, and upper respiratory tract infection.
^dFungal infection includes candida infection, oesophageal candidiasis, oral candidiasis and oropharyngeal candidiasis.
^eSepsis includes bacteraemia, sepsis, and septic shock.
^fNeutropenia includes neutropenia and neutrophil count decreased.
^gAnaemia includes anaemia and serum ferritin decreased.
^hThrombocytopenia includes platelet count decreased and thrombocytopenia.
ⁱLymphopenia includes lymphocyte count decreased and lymphopenia.
^jEvents graded using American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria.
^kClinical Tumour Lysis Syndrome was graded based on Cairo-Bishop.
^lCardiac arrhythmias include bradycardia, sinus bradycardia, sinus tachycardia, supraventricular tachycardia, and tachycardia.
^mAbdominal pain includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.
ⁿRash includes rash, rash erythematous, rash macular, rash maculo-papular, rash popular, rash pruritic, rash pustular and rash vesicular.
^oMusculoskeletal pain includes back pain, bone pain, flank pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain, pain in extremity, and spinal pain.
^pinjection site reactions include injection site bruising, injection site erythema, injection site hypertrophy, injection site inflammation, injection site mass, injection site nodule, injection site oedema, injection ^site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, and injection site urticaria.
^qFatigue includes asthenia, fatigue, and lethargy.
^rPyrexia includes body temperature increased and pyrexia.
^sOedema includes face oedema, generalised oedema, oedema, oedema peripheral, peripheral swelling, swelling, decreased and hyponatraemia. and swelling face.
^tBlood sodium decreased includes blood sodium decreased and hyponatraemia.